Healthcare Industry News:  radiopharmaceuticals 

Biopharmaceuticals Personnel

 News Release - April 18, 2007

Molecular Insight Pharmaceuticals, Inc. Announces Appointment of Brian Abeysekera, Ph.D., as Vice President, Manufacturing

CAMBRIDGE, Mass.--(HSMN NewsFeed)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI ) announced the appointment of Brian Abeysekera, Ph.D., to the newly-created position of Vice President, Manufacturing. He joins Molecular Insight after more than 20 years of increasing responsibility at MDS Nordion, the world's leading manufacturer of radioisotopes, where he was most recently Director, Applied R&D.

"Brian is a recognized leader in the highly specialized field of radiopharmaceutical development who should make an immediate contribution to Molecular Insight. His broad experience spans radionuclide production, radiochemistry, quality assurance and regulatory affairs," said John W. Babich, Ph.D., President and Chief Scientific Officer of Molecular Insight. "We look forward to Brian's proven expertise and leadership abilities to guide the manufacture of quality material for our clinical programs and to prepare for the commercial scale-up of our strong pipeline of targeted radiotherapeutics and molecular imaging pharmaceuticals."

"Molecular Insight is the leading innovator in the discovery and development of molecular targeting radiopharmaceuticals, and I am very pleased to be joining the company at this exciting stage of its rapid growth," said Dr. Abeysekera. "I look forward to leading a talented team toward continued progress in the manufacture of the company's robust pipeline of innovative new drug candidates and toward further expansion of its unique radiolabeling technology platforms."

Among his many achievements during his 22-year career at Nordion, Dr. Abeysekera helped establish MDS Nordion as a cGMP supplier of sterile pharmaceuticals in the United States and Canada, designed, developed and validated aseptic manufacturing facilities, directed scale up from clinical to commercial manufacturing, and developed chemistry and manufacturing sections for numerous small molecule and biologic products to support FDA submissions. Dr. Abeysekera holds a Ph.D. in synthetic organic chemistry from the University of British Columbia.

About Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals (NASDAQ: MIPI ) is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve healthcare for patients with life-threatening diseases. The company is focused on discovering, developing and commercializing innovative and targeted radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology. Molecular Insight's lead targeted radiotherapeutic product candidates, Azedra and Onalta, are being developed for detection and treatment of cancer. The company's lead molecular imaging pharmaceutical product candidate, Zemiva, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. In addition, the company has a growing pipeline of product candidates resulting from application of its proprietary platform technologies to new and existing compounds. Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts and its website address is: www.molecularinsight.com.

Forward-Looking Statements

Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about the development of Azedra(TM), Onalta (TM), Zemiva(TM) and our other product candidates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Molecular Insight to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Molecular Insight undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.


Source: Molecular Insight Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.